Bausch Health Companies Inc. (TSX:BHC)
12.33
-0.19 (-1.52%)
Nov 19, 2026, 3:50 PM EST
Bausch Health Companies Revenue
Bausch Health Companies had revenue of $2.94B USD in the quarter ending September 30, 2026, with 9.70% growth. This brings the company's total for the last twelve months to $11.11B, up 10.81% year-over-year. In the year 2025, Bausch Health Companies had annual revenue of $10.27B with 6.66% growth.
Revenue (ttm)
$11.11B
Revenue Growth
+10.81%
P/S Ratio
0.29
Revenue / Employee
$547.44K
Employees
20,300
Market Cap
4.61B CAD
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full Bausch Health Companies breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 10.27B | 641.00M | 6.66% |
| Dec 31, 2024 | 9.63B | 868.00M | 9.91% |
| Dec 31, 2023 | 8.76B | 633.00M | 7.79% |
| Dec 31, 2022 | 8.12B | -310.00M | -3.68% |
| Dec 31, 2021 | 8.43B | 407.00M | 5.07% |
| Dec 31, 2020 | 8.03B | -574.00M | -6.67% |
| Dec 31, 2019 | 8.60B | 221.00M | 2.64% |
| Dec 31, 2018 | 8.38B | -344.00M | -3.94% |
| Dec 31, 2017 | 8.72B | -950.00M | -9.82% |
| Dec 31, 2016 | 9.67B | -773.00M | -7.40% |
| Dec 31, 2015 | 10.45B | 2.24B | 27.31% |
| Dec 31, 2014 | 8.21B | 2.44B | 42.23% |
| Dec 31, 2013 | 5.77B | 2.29B | 65.77% |
| Dec 31, 2012 | 3.48B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Apotex Health | 3.21B |
| Curaleaf Holdings | 1.92B |
| Green Thumb Industries | 1.76B |
| Verano Holdings | 1.20B |
| Vireo Growth | 956.44M |
| Knight Therapeutics | 563.45M |
| Aurora Cannabis | 314.07M |
| Cronos Group | 292.73M |
Bausch Health Companies News
- 8 hours ago - Bausch Health's Aesthetic Business, Solta Medical, Surpasses 10 Million Treatments Worldwide - PRNewsWire
- 8 days ago - Bausch Health price target raised to $9 from $7 at Barclays - TheFly
- 13 days ago - Bausch Health's Gastroenterology Business, Salix, to Present New Data on Cirrhosis Trends and Severe Alcohol-Associated Hepatitis at The Liver Meeting® 2026 - PRNewsWire
- 21 days ago - Bausch Health price target raised to $8 from $6.50 at Jefferies - TheFly
- 22 days ago - Bausch Health Companies Earnings Call Transcript: Q3 2026 - Transcripts
- 22 days ago - Bausch Health Companies Earnings release: Q3 2026 - Filings
- 22 days ago - Bausch Health Companies Slides: Q3 2026 - Filings
- 22 days ago - Bausch Health Companies Quarterly report: Q3 2026 - Filings